Olema Strategy and Business Model

Executive Overview

Founded in 2006 and headquartered in San Francisco, Olema is a clinical-stage biopharmaceutical company focused on endocrine-driven cancers, especially estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. Olema’s strategy is unusually focused: rather than building a broad oncology portfolio first, it is trying to create a differentiated oral endocrine therapy platform around palazestrant (OP-1250), its lead product candidate, and use that program to establish credibility in endocrine-resistant disease. As of 2024, the company’s priorities were to move palazestrant into pivotal development, generate more combination data with established targeted therapies, and preserve the capital needed to fund later-stage trials. Olema’s industry sits at the intersection of biotechnology, oncology drug development, and specialty pharmaceuticals. Its physical footprint is U.S.-centered, but its clinical footprint is broader because later-stage oncology trials typically require multinational site networks. Economically, Olema is still a development company rather than a commercial pharma company: it remained pre-revenue through FY2023, with no marketed product sales, so investors and partners mainly evaluate it on clinical data quality, differentiation versus other estrogen receptor therapies, and balance-sheet runway.

Olema at a Glance

Logo
Common name	Olema
Full legal name	Olema Pharmaceuticals, Inc.
Headquarters	San Francisco, California, United States
Ownership	Public company
Ticker	OLMA
Exchange	NASDAQ
Market Cap	$915.40M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Incorporated in 2006; became a Nasdaq-listed public company in 2020; advanced palazestrant into pivotal development in 2024
Industry or industries	Clinical-stage biotechnology; oncology biopharmaceuticals; breast-cancer therapeutics
Key products or services	Palazestrant (clinical-stage oral endocrine therapy candidate); oncology drug discovery and development
Geographic footprint	U.S.-based corporate footprint with multinational clinical-trial activity
Business segments as officially reported	One operating and reportable segment, as of FY2023 reporting
Company website	https://www.olema.com

1. What Is the Strategy of Olema?

Olema’s public materials through 2024 describe a focused oncology strategy centered on endocrine-driven breast cancer rather than a broad, multi-tumor portfolio. Using the Playing to Win framework, the strategy looks like this:

1. 1a. What is the winning aspiration of Olema?

   Olema’s winning aspiration is to improve outcomes in endocrine-driven cancers by developing a better oral therapy against the estrogen receptor, starting with metastatic breast cancer. In practical terms, “winning” means getting palazestrant through registrational development and establishing it as a clinically meaningful option in patients whose tumors have become resistant to standard endocrine treatment. As of 2024, Olema had not publicly set long-range revenue or market-share targets in the style of a mature commercial pharma company; its nearer-term measurable ambition is clinical differentiation, successful pivotal execution, and eventual regulatory approval.

2. 1b. Where does Olema play?

   Olema is playing in a narrowly defined but commercially important part of oncology: ER+/HER2- breast cancer, particularly advanced or metastatic disease where endocrine resistance emerges after prior therapy, including after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor use. The company’s initial field of play is not all solid tumors or even all breast-cancer subtypes. It is concentrated on the hormone-receptor biology that drives a large share of breast-cancer treatment decisions. Over time, the company has signaled interest in combinations and adjacent endocrine-driven settings, but the core battlefield remains resistant ER-driven disease.

3. 1c. How does Olema plan to win?

   Olema appears to be trying to win through molecular differentiation and focused clinical positioning. The company presents palazestrant as an oral small molecule designed to both strongly antagonize and degrade the estrogen receptor, with the goal of overcoming resistance mechanisms that weaken older endocrine therapies. That positioning matters because the competitive benchmark is not just other experimental drugs; it is also injectable fulvestrant, generic aromatase inhibitors, and newer oral ER-targeting agents. Olema’s implicit “how to win” is to show that palazestrant can combine strong efficacy, useful tolerability, oral convenience, and compatibility with combination regimens, making it attractive both as monotherapy and as a backbone endocrine partner.

4. 1d. What capabilities must Olema have in place?

   To execute that strategy, Olema needs a specific set of capabilities: strong medicinal chemistry and translational biology in estrogen-receptor signaling; breast-cancer clinical-development expertise; biomarker and resistance-mechanism insight; regulatory execution for later-stage studies; and dependable external manufacturing and clinical-operations management. Because Olema is a clinical-stage biotech rather than a fully integrated pharma company, vendor orchestration is also a core capability. It must manage contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), trial sites, and specialist laboratories without losing speed or quality.

5. 1e. What management systems does Olema require?

   Olema needs management systems built around milestone discipline. As of FY2023, the company reported one operating and reportable segment, which fits a centralized governance model. The key systems are portfolio prioritization, trial-enrollment tracking, safety and pharmacovigilance oversight, quality and good manufacturing practice (GMP) compliance, cash-runway management, and board-level decision making tied to data readouts. In a company this focused, management systems matter because a delay in enrollment, a chemistry-manufacturing issue, or a capital-markets misstep can materially alter strategic options.

2. What Are the Current Strategic Initiatives of Olema?

As of 2024, Olema’s publicly visible strategic initiatives were tightly linked to turning palazestrant from a promising clinical asset into a registrational program.

• Advance palazestrant into pivotal development. The most important initiative was the launch of OPERA-01, Olema’s pivotal Phase 3 program for palazestrant monotherapy in ER+/HER2- metastatic breast cancer after prior endocrine therapy and CDK4/6 inhibition. This is the company’s central value-creation program.
• Build a combination-development franchise around palazestrant. Olema has also publicly discussed combination development with established targeted therapies used in ER+/HER2- disease, including CDK4/6 inhibition and PI3K-pathway therapy. The strategic logic is straightforward: in breast cancer, the most valuable endocrine agents are often the ones that can serve as a flexible backbone across multiple combination regimens.
• Differentiate on endocrine resistance biology. Olema’s data strategy has emphasized resistant disease, including patients whose tumors may carry ESR1-driven resistance biology. That matters because a new ER-targeting therapy must show more than basic activity; it must show why it deserves a place in a crowded post-CDK4/6 landscape.
• Scale later-stage development infrastructure without overbuilding. As a pre-commercial biotech, Olema has to add clinical, regulatory, data, and manufacturing readiness for pivotal studies while still preserving capital. The company’s operating challenge is to become “late-stage capable” without taking on the fixed-cost structure of a full commercial pharma company too early.
• Broaden the pipeline beyond a single lead asset. Olema has continued to discuss earlier-stage discovery and development work aimed at endocrine-driven cancers and resistance mechanisms. Even if palazestrant dominates the near-term story, the strategic need is to reduce single-asset dependence over time.

3. What Is the Business Model of Olema?

Olema’s current business model is that of a clinical-stage biotechnology company, not yet a commercial drug company.

• What customers actually buy: As of 2024, no customers were buying an approved Olema product because the company had no marketed therapies. In the future, what oncologists, payers, and patients would buy is a branded prescription oncology therapy, likely starting with palazestrant.
• Recurring or repeat-driven versus one-time: If approved, an oral breast-cancer therapy would create repeat prescription demand over the course of treatment, which is structurally recurring. Today, however, Olema’s cash inflows are primarily one-time financing events such as equity offerings rather than recurring operating revenue.
• How pricing power works: Future pricing power would depend on clinical differentiation, line-of-therapy positioning, label breadth, and combination utility. In oncology, strong data can support premium pricing, but pricing is constrained by competing therapies, payer scrutiny, and the economics of combination treatment.
• Why the business mix matters: For Olema, the future mix between monotherapy and combination therapy, U.S. self-commercialization versus partnerships, and early-line versus later-line use would heavily influence revenue potential. A drug used only in a narrow refractory segment has a very different economic profile from one used as a backbone in broader combinations.
• What drives gross margin, operating margin, and cash generation: If approved, a small-molecule oral oncology drug would typically have attractive gross margins relative to biologics. But Olema’s near-term operating economics are driven by research and development expense, clinical-trial scale, manufacturing readiness spending, and general and administrative costs. Cash generation today is negative by design because the company is investing ahead of revenue.
• Revenue model: At this stage the revenue model is best described as pipeline monetization deferred into the future. The eventual model could include direct drug sales, ex-U.S. licensing, milestones, or partnerships, but as of FY2023 Olema remained pre-revenue with no product sales.

4. What Products and/or Services Does Olema Sell?

As of 2024, Olema did not sell approved commercial products. Its economic value is tied to its development pipeline.

• Palazestrant (OP-1250): This is Olema’s lead product candidate and clearly its most important asset. It is an oral estrogen receptor antagonist designed to block and degrade the receptor, with development focused on ER+/HER2- metastatic breast cancer.
• Earlier-stage pipeline programs: Olema has also discussed additional discovery and development efforts aimed at endocrine-driven cancers and resistance pathways. As of 2024, however, these programs were strategically secondary to palazestrant.
• Services: Olema is not a services business. It does not sell contract research, manufacturing, diagnostics, or software. Its “offering” is the future potential of a differentiated oncology therapy.

In practical terms, palazestrant appears to drive nearly all of Olema’s near-term strategic importance. There is no meaningful legacy product base to support the company while newer offerings scale, which is common in clinical-stage biotech but increases execution risk.

5. What Are the Key Competitors or Peers of Olema?

Olema competes less with local geographic peers and more with other companies, products, and drug classes trying to own the ER+/HER2- endocrine-therapy pathway.

Beyond named companies, Olema also competes with incumbent standards of care such as fulvestrant and generic aromatase inhibitors. For a new endocrine therapy, beating older treatment habits can be as important as beating another development-stage biotech.

6. What Is the Marketing Strategy of Olema?

As of 2024, Olema did not have a traditional commercial marketing strategy because it had no approved products. Its current external-facing strategy is better understood as scientific communication and market shaping rather than product marketing.

• Medical and scientific visibility: Presenting data at oncology meetings, publishing clinical updates, and engaging key opinion leaders are central. In biotech, this is how a company builds credibility before launch.
• Trial recruitment support: Awareness among investigators and referral networks matters because enrollment speed affects program timelines.
• Investor communications: For a pre-revenue biotech, access to capital is strategically important, so clear communication with investors is part of the broader “market-facing” function.
• Future-state marketing: If palazestrant is approved, Olema would likely need a highly targeted oncology marketing model aimed at medical oncologists, breast-cancer specialists, and payer decision makers rather than broad consumer advertising. That is an inference from the product category and customer concentration, not a statement of a fully built current infrastructure.

So far, marketing does not appear to be Olema’s main differentiator. The real differentiator is supposed to be the molecule and the data.

7. What Are the Key Customer Segments of Olema?

Because Olema is pre-commercial, its customer picture has to be split between current operating stakeholders and future economic customers.

• Current operating stakeholders: Clinical investigators, trial sites, participating patients, regulators, and specialist service providers are the groups Olema interacts with most today.
• Future prescribers: The core prescribing audience would be medical oncologists and breast-cancer specialists treating ER+/HER2- metastatic disease in academic centers and community oncology settings.
• Future payers and access intermediaries: Commercial insurers, Medicare-related channels in the United States, pharmacy benefit managers, and ex-U.S. reimbursement bodies would matter because oncology pricing and formulary access shape uptake.
• Patients and caregivers: Oral convenience, tolerability, and duration on therapy can influence adherence and treatment preference, especially versus injectable alternatives.
• Potential partners: Ex-U.S. pharmaceutical partners, licensing counterparties, or co-development allies are also important quasi-customers in a strategic sense because partnership structure could become part of the monetization model.

Olema is not diversified across many end markets. Its exposure is concentrated in hormone-receptor-positive breast cancer, which increases focus and strategic clarity but also concentration risk.

8. What Is the Sales Model of Olema?

As of 2024, Olema had no commercial sales model in operation because it had no approved product. Its current go-to-market activity is clinical rather than commercial: it works through investigators, trial sites, CROs, and medical communication channels to generate data and move programs forward.

If palazestrant reaches the market, the logical sales model would likely be a focused specialty-oncology model:

• Direct U.S. specialty sales: Breast-cancer prescribing is concentrated enough that a relatively focused field force could address many high-value accounts.
• Medical science liaisons and KOL engagement: In oncology, medical affairs often matters as much as classic sales promotion.
• Specialty pharmacy and reimbursement support: Oral oncology drugs usually need tight coordination around prior authorization, dispensing, and patient support.
• Ex-U.S. partnering: For a company of Olema’s scale, partnering outside the United States would be a plausible route. This is an inference based on industry practice, not a declared exclusive strategy.

Channel structure would matter strategically. A focused direct model can support high customer intimacy and sharper scientific messaging, while partnership channels can expand geographic reach without building a full global commercial organization.

9. In What Geographies Does Olema Operate?

Olema’s physical operating footprint is relatively concentrated, but its development footprint is broader.

• Headquarters and core corporate base: Olema is headquartered in San Francisco, California.
• Primary operating center: As of FY2023 reporting, the company’s corporate infrastructure was centered in the United States rather than spread across multiple large regional business units.
• Clinical-trial geography: As palazestrant moved toward pivotal development in 2024, Olema’s clinical footprint was becoming more international, which is typical for later-stage oncology studies that need larger patient populations and faster enrollment.
• Manufacturing and service network geography: Like many biotech companies, Olema relies on third-party partners for manufacturing, research support, and clinical operations, which means parts of its effective operating network can be geographically dispersed even when the company itself is not.

In short, Olema is corporately U.S.-centered but operationally networked. It does not resemble a multinational pharma company with broad sales offices, owned plants, and country-level business units.

10. Who Are the Owners of Olema?

Olema is a publicly traded company listed on Nasdaq under the ticker OLMA. As of the company’s 2024 proxy materials, Olema did not disclose a controlling shareholder. That ownership profile is typical of development-stage biotech companies, which are usually owned primarily by institutional investors, specialist healthcare funds, passive asset managers, insiders, and retail shareholders rather than by a strategic parent.

Because 5% beneficial ownership positions in biotech can change materially over time, the most current view of large shareholders should be taken from Olema’s latest proxy statement and recent Schedule 13G or 13D filings.

11. How Is Olema Organized?

As of FY2023, Olema reported one operating and reportable segment. That is consistent with a practical organization built around a small number of cross-functional functions rather than separate profit centers.

• Research and preclinical development: Discovery biology, medicinal chemistry, and translational science.
• Clinical development: Trial design, medical oversight, data analysis, and interaction with investigators.
• Technical operations: Chemistry, manufacturing, controls, supply planning, and external manufacturing oversight.
• Regulatory and quality: Regulatory submissions, compliance, pharmacovigilance, and quality systems.
• General and administrative: Finance, legal, human resources, investor relations, and public company infrastructure.

Olema is therefore organized more like a program-centric biotech than a diversified pharmaceutical portfolio company. The lead asset, palazestrant, likely drives most major resource-allocation decisions.

12. How Does Olema Operate?

On a day-to-day basis, Olema operates as a molecule-development company. Its job is not to run large factories or nationwide sales teams; it is to convert scientific hypotheses into approvable drugs.

1. Discover and optimize compounds. Olema’s internal scientific work focuses on endocrine biology and resistance mechanisms relevant to ER-driven cancers.
2. Generate preclinical evidence. The company evaluates potency, selectivity, pharmacology, and anti-tumor activity before taking candidates into human studies.
3. Manufacture clinical supply through partners. Drug substance and drug product work are typically handled through specialist third parties under GMP controls.
4. Run clinical trials. This includes site selection, patient enrollment, safety monitoring, dosing, biomarker work, and statistical analysis.
5. Engage regulators. Olema must align on trial design, endpoints, comparators, and manufacturing requirements as programs mature.
6. Raise and allocate capital. Since there is no product cash flow, operating continuity depends on careful financing and burn-rate management.

The main operational bottlenecks are typical for oncology biotech: patient recruitment, data maturity, comparator selection, manufacturing readiness, and competitive trial noise from larger companies pursuing similar targets.

13. What Are the Growth Opportunities for Olema?

Olema’s growth opportunities are closely tied to the breadth of the palazestrant opportunity and the company’s ability to reduce single-asset risk.

• Management-stated opportunity: registrational success in metastatic breast cancer. The clearest opportunity is approval and launch of palazestrant in ER+/HER2- metastatic breast cancer after prior endocrine therapy and CDK4/6 inhibition.
• Combination expansion. If palazestrant proves to be a strong partner with CDK4/6 inhibitors or PI3K-pathway agents, its commercial relevance could expand materially because combination therapy is central to this disease area.
• Earlier-line use. Moving from later-line refractory settings toward earlier lines of treatment would expand addressable patients and treatment duration, though it also raises evidentiary and competitive hurdles.
• Biomarker-defined subpopulations. Differentiation in ESR1-mutant or other endocrine-resistant subgroups could help Olema carve out clinical relevance even in a crowded market.
• Pipeline expansion and business development. Additional internally discovered or externally sourced assets could help Olema evolve from a single-program company into a broader endocrine-oncology platform.
• Geographic partnerships. Ex-U.S. licensing or co-commercialization could create non-dilutive capital and broaden reach without requiring Olema to build a full global infrastructure.

The main constraints are equally clear: clinical risk, regulatory uncertainty, strong competition from better-capitalized breast-cancer players, payer scrutiny, and the capital intensity of later-stage development.

14. What Is the History of Olema?

Olema was incorporated in Delaware in 2006. Public company materials emphasize the company’s scientific focus on endocrine-driven cancers more than a single-founder narrative, so its identity has been shaped primarily by its research agenda rather than by a highly visible founding story.

Over time, Olema built itself around small-molecule approaches to hormone-receptor biology, with a particular focus on the estrogen receptor. The company’s most important historical milestone was its evolution into a public company: Olema completed its initial public offering in 2020 and began trading on Nasdaq under the ticker OLMA.

From there, the company’s history is mainly the history of palazestrant: moving the molecule through preclinical work, early clinical testing, and then into a later-stage development strategy. By 2023 and 2024, Olema’s public updates increasingly centered on building the data package and operational readiness needed for pivotal development.

Unlike many older pharmaceutical companies, Olema’s history has not been defined by major acquisitions, legacy brands, or restructuring episodes. It remains, at least through 2024, a relatively pure-play clinical-stage oncology biotech.

15. What Are the Key Suppliers to Olema?

Suppliers matter to Olema because the company relies heavily on specialized external partners rather than vertically integrated internal infrastructure.

• Contract development and manufacturing organizations: These partners produce active pharmaceutical ingredient, formulate drug product, package clinical supply, and support scale-up.
• Contract research organizations: CROs help with trial management, site monitoring, data management, and regulatory support.
• Specialty laboratories: Biomarker testing, central lab work, and pharmacokinetic analysis are important in oncology development.
• Clinical trial sites and investigator networks: These are not “suppliers” in the manufacturing sense, but they are critical operating inputs because enrollment speed and quality shape development timelines.
• Raw-material and comparator-drug providers: Access to inputs and comparator therapies can matter operationally in later-stage studies.

Olema’s public filings emphasize dependence on third parties, but they do not foreground a single named supplier in the way an industrial company might. Strategically, supplier structure matters because a small biotech can be vulnerable to single-source dependencies, long lead times, or manufacturing deviations.

16. How Does the Supply Chain of Olema Function?

Olema’s supply chain is a clinical-development supply chain, not yet a mass-commercial pharmaceutical distribution network.

1. Sourcing and synthesis: Raw materials and intermediates are sourced, then converted into active pharmaceutical ingredient by third-party manufacturers.
2. Drug product manufacturing: The active ingredient is formulated into oral dosage form, tested for quality, and packaged for clinical use.
3. Clinical packaging and labeling: Trial material must be labeled to protocol, country, and regulatory requirements.
4. Distribution to study sites: Product is shipped to investigator sites and tracked carefully to avoid stockouts, expiry issues, or protocol deviations.
5. Returns, reconciliation, and stability management: Clinical supply requires tight control over inventory, chain of custody, and shelf-life data.

For Olema, supply-chain performance matters strategically because late-stage oncology trials can be delayed by relatively small failures in manufacturing, release testing, or site-level product availability. The fact that palazestrant is an oral small molecule is helpful operationally relative to more complex biologics, but it does not remove the need for disciplined GMP execution.

17. What Are the Key Assets of Olema?

Olema is not especially asset-heavy in the industrial sense of owning plants, fleets, or retail locations. Its economically critical assets are mainly intangible and financial.

• Palazestrant and its clinical data package: This is the company’s most important asset by far.
• Intellectual property: Composition, formulation, use, and know-how around estrogen receptor targeting are central to long-term value.
• Cash, cash equivalents, and marketable securities: For a pre-revenue biotech, balance-sheet runway is a strategic asset, not just a financial statistic.
• Scientific and clinical talent: The ability to interpret resistance biology and design smart trials is a core competitive resource.
• External partner network: Reliable CROs, CDMOs, labs, and site relationships function like infrastructure even if Olema does not own them.

That asset profile has an important implication: Olema’s value can move sharply on data, IP, and cash-runway changes because those assets carry more weight than physical capital.

18. What Is the R&D Strategy of Olema?

R&D is the center of Olema’s strategy. The company’s approach appears to combine deep disease focus with molecule-specific differentiation.

• Concentrate on endocrine biology: Olema has chosen depth over breadth, focusing on estrogen-receptor signaling and resistance rather than spreading early across many oncology mechanisms.
• Use palazestrant as the lead validation vehicle: Most near-term R&D value creation runs through showing that palazestrant can outperform or complement existing endocrine therapy options.
• Study combination potential early: In ER+/HER2- breast cancer, endocrine agents rarely succeed in isolation from the broader treatment ecosystem. Olema’s combination work reflects that reality.
• Build around resistance mechanisms: The research logic is not simply to make another endocrine therapy, but to address why tumors stop responding to prior endocrine therapy.
• Keep discovery optionality alive: Even while palazestrant dominates, Olema needs follow-on programs to reduce concentration risk and extend the platform.

As with most biotech companies at this stage, R&D spending likely represents the largest use of capital. The challenge is to keep the portfolio focused enough to preserve runway while still creating a second act beyond the lead molecule.

19. What Is the Finance Strategy of Olema?

Olema’s finance strategy is shaped by one basic fact: it is a pre-revenue clinical-stage biotech. That means finance is less about optimizing earnings and more about funding value-inflecting milestones while preserving strategic flexibility.

• Prioritize cash runway: The company needs enough liquidity to reach major clinical and regulatory milestones without being forced into unfavorable financing windows.
• Fund R&D first: Capital allocation is naturally skewed toward clinical development, manufacturing readiness, and supporting data generation rather than broad commercial buildout.
• Rely primarily on equity financing: Like many development-stage biotech companies, Olema has historically depended more on public-equity capital than on operating cash flow.
• Avoid premature fixed-cost expansion: Building too much commercial infrastructure too early would reduce runway without improving the clinical probability of success.
• Keep optionality for partnerships: Ex-U.S. or asset-level deals could provide non-dilutive capital if the data support them.

Olema does not have the capital-allocation profile of a mature pharma company. There is no dividend story, no buyback story, and no operating-margin story yet. The finance strategy is really a milestone-financing strategy.

20. How Companies Like Olema Leverage Independent Consultants through Umbrex

Companies like Olema engage Umbrex when they need highly experienced problem solvers without hiring a large consulting team. Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. For a clinical-stage biotech like Olema, that model is useful when management needs focused help on a high-stakes decision, a capability build, or a time-bound workstream tied to clinical, commercial, operating, or financing milestones.

• Phase 3 strategy review: pressure-test the target product profile, comparator strategy, endpoint logic, and scenario planning for palazestrant’s registrational path.
• Combination portfolio prioritization: evaluate which partner classes and trial sequences offer the best risk-adjusted value in CDK4/6, PI3K, AKT, and adjacent pathways.
• Commercial opportunity sizing: build a bottom-up view of U.S. and ex-U.S. demand by treatment line, biomarker subgroup, and prescriber segment.
• Ex-U.S. partnering strategy: identify the best geographies and partner profiles for licensing, co-development, or co-commercialization.
• Launch-readiness blueprint: design a lean specialty-oncology commercial model for a future U.S. launch, including field force sizing, medical affairs interfaces, and patient-support requirements.
• Pricing and market-access planning: assess how an oral ER-targeting therapy might position against fulvestrant, elacestrant, and combination regimens in payer negotiations.
• Clinical-operations improvement: create dashboards and operating rhythms for trial enrollment, site productivity, vendor governance, and milestone tracking.
• Technical-operations and supply strategy: review CMC network design, clinical-supply risk, inventory planning, and scale-up readiness for later-stage development.
• Capital planning and investor narrative support: link clinical milestones, spend plans, and strategic options into a coherent financing roadmap.
• Business development screening: scan adjacent endocrine-oncology assets or enabling technologies that could reduce Olema’s single-asset concentration over time.